Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$2.12 - $4.18 $22,145 - $43,664
-10,446 Reduced 32.65%
21,552 $87,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $10.04 $85,114 - $321,259
31,998 New
31,998 $86,000
Q1 2023

May 15, 2023

SELL
$5.21 - $14.05 $97,411 - $262,692
-18,697 Reduced 9.43%
179,550 $1.59 Million
Q4 2022

Feb 14, 2023

BUY
$4.69 - $8.36 $557,401 - $993,577
118,849 Added 149.69%
198,247 $987,000
Q3 2022

Nov 14, 2022

BUY
$5.7 - $8.68 $271,770 - $413,853
47,679 Added 150.32%
79,398 $461,000
Q2 2022

Aug 08, 2022

BUY
$5.04 - $14.05 $159,863 - $445,651
31,719 New
31,719 $175,000

Others Institutions Holding THRX

About Theseus Pharmaceuticals, Inc.


  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.